Clinical trials: Tregs
Type 1 Diabetes Mellitus
Immunotherapy with Autologous Tregs in T1DM
Type 1 diabetes (T1D) is an autoimmune disease characterized by a progressive immune distruction of pancreat beta cells and deterioration of endogenous insulin secretion.
- Trial name
- NCT06708780
- Testing
- Ex vivo Expanded Human Autologous Regulatory T Cells, Routine Care
- Where
- China
- Volunteers
- 20 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Polymorphic Light Eruption, Psoriasis
Regulatory T Cells (Tregs) in Polymorphic Light Eruption
Polymorphic light eruption (PLE) is a photodermatosis with an extremely high prevalence, particularly among young women (up to 20%).
- Conditions
- Polymorphic Light Eruption, Psoriasis, Atopic Eczema
- Trial name
- NCT00555178
- Where
- 2 sites in Austria
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Medical University of Graz
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer
This is a feasibility study to assess the effectiveness of cetuximab when administered with low dose oral cyclophosphamide. Patients with metastatic squamous cell cancer of head and neck who have progressed on first line…
- Trial name
- NCT01581970
- Testing
- Cyclophosphamide, Cetuximab
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Liver Transplant
Liver Transplantation With Tregs at MGH
This is a single-center, prospective, open-label, non-randomized clinical trial exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients.
- Trial name
- LITTMUS-MGH (NCT03577431)
- Testing
- arTreg-CSB, leukapheresis, cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ulcerative Colitis
Low Dose IL-2 for Ulcerative Colitis
The purpose of this study is to determine the safety and maximum effective dose (MED) of Interleukin-2 in subjects with moderate-to-severe ulcerative colitis.
- Trial name
- NCT02200445
- Testing
- Interleukin-2 (aldesleukin).
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Scott B. Snapper, MD PHD
Acute Respiratory Distress Syndrome Due to Disease Caused by 2019-nCoV
Tregs for the Treatment of Acute Respiratory Distress Syndrome (ARDS) Associated With COVID-19 (regARDS)
In patients with Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19 inflammatory syndrome, the administration of Treg cells is a novel treatment complementary to other pharmacologic interventions that potentially…
- Trial name
- regARDS (NCT05027815)
- Testing
- Cryopreserved Ex Vivo Expanded Polyclonal CD4+CD127lo/-CD25+ T Regulatory Cells
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- Jeffrey Bluestone
Sepsis, Septic Shock
Immune Failure in Critical Therapy (INFECT) Study
Patients admitted to intensive care units (ICU) are at high risk of developing secondary infections, and this is in part due to dysfunction or failure of their 'germ killing' functions (the immune system).
- Trial name
- INFECT (NCT02186522)
- Where
- 4 sites in United Kingdom
- Volunteers
- 168 people
- Sponsor
- University of Edinburgh